keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab

keyword
https://www.readbyqxmd.com/read/29146761/comparison-among-adjuvant-treatments-for-primary-pterygium-a-network-meta-analysis
#1
Ellen Carrara Fonseca, Eduardo Melani Rocha, Gustavo Viani Arruda
PURPOSE: Pterygium is a frequent ocular disease, where the major challenge is the high level of recurrence after its surgical removal. We performed a network meta-analysis to identify, among several adjuvant treatments for primary pterygium, which is the best to prevent recurrence. METHODS: A search was conducted using PubMed, Scientific Electronic Library Online, Latin American and Caribbean Centre on Health Sciences and Cochrane Eyes and Vision Group Trials Register between 1993 and 2015 for randomisedclinical trials (RCTs) comparing adjuvant treatments following primary pterygium surgery...
November 16, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29146617/cure-in-advanced-renal-cell-cancer-is-it-an-achievable-goal
#2
Dhanusha Sabanathan, John J Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney
BACKGROUND: Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%-30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29146306/real-world-vision-in-age-related-macular-degeneration-patients-treated-with-single-anti-vegf-drug-type-for-1-year-in-the-iris-registry
#3
Prethy Rao, Flora Lum, Kevin Wood, Craig Salman, Bhavya Burugapalli, Rebecca Hall, Sukhminder Singh, David W Parke, George A Williams
PURPOSE: The purpose of this study is to compare real-world visual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti-vascular endothelial growth factor (VEGF) drug monotherapy for 1 year from the American Academy of Ophthalmology (AAO) Intelligent Research in Sight (IRIS) Registry. DESIGN: Retrospective, nonrandomized, comparative study. PARTICIPANTS: IRIS Registry patients with nAMD who received bevacizumab, ranibizumab, or aflibercept only for 1 year between 2013-2016...
November 13, 2017: Ophthalmology
https://www.readbyqxmd.com/read/29145816/renal-failure-during-chemotherapy-renal-biopsy-for-assessing-subacute-nephrotoxicity-of-pemetrexed
#4
Maureen Assayag, Philippe Rouvier, Marion Gauthier, Ghania Costel, Philippe Cluzel, Lucile Mercadal, Gilbert Deray, Corinne Isnard Bagnis
BACKGROUND: Pemetrexed, a multitargeted antifolate cytotoxic agent, is currently used primarily in combination with cisplatin for metastatic non-small cell lung cancer and for malignant mesothelioma. Acute renal toxicity of pemetrexed has been recently described with polychemotherapy, in which the individual responsibility of each drug is difficult to establish. Only one recent report documents renal involvement in long-term exposed patients. CASE PRESENTATION: We report on a case of rapidly progressive nephropathy leading to the cessation of platinum salts and the secondary interruption of pemetrexed and bevacizumab...
November 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29145602/genotype-based-selection-of-treatment-for-patients-with-advanced-colorectal-cancer-seticc-a-pharmacogenetic-based-randomized-phase-ii-trial
#5
A Abad, E Martínez-Balibrea, J M Viéitez, V A Orduña, P García Alfonso, J L Manzano, B Massutí, M Benavides, A Carrato, M Zanui, J Gallego, C Grávalos, V Conde, M Provencio, M Valladares, R Salazar, J Sastre, C Montagut, F Rivera, E Aranda
Background: There has been little progress toward personalized therapy for patients with metastatic colorectal cancer (mCRC). TYMS-3' untranslated region (UTR) 6 bp ins/del and ERCC1-118C/T polymorphisms were previously reported to facilitate selecting patients for fluoropyrimidine-based treatment in combination with oxaliplatin as first-line therapy. We assessed the utility of these markers in selecting therapy for patients with mCRC. Patients and methods: This randomized, open-label phase II trial compared bevacizumab plus XELOX (control) versus treatment tailored according to TYMS-3'UTR 6 bp ins/del and ERCC1-118C/T polymorphisms...
November 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29142888/effect-of-intravitreal-injection-of-bevacizumab-on-acute-central-serous-chorioretinopathy-patients-who-visited-feiz-hospital-during-2014-2015-period
#6
Mohamad Reza Akhlaghi, Cobra Nasrollahi, Seyed Mohamad Namgar, Farzan Kianersi, Ali Reza Dehghani, Reza Arefpour
Background: Aim of this clinical trial is the evaluation of the effect of intravitreal injection of bevacizumab on acute central serous chorioretinopathy (CSC). Materials and Methods: In a nonrandomized clinical trial, 36 CSC eyes (with <1-month disease history) were examined. Initially, all the patients underwent posterior and anterior segment examinations as well as complete eye examination to evaluate the best spectacle-corrected visual acuity (BSCVA). Then, optical coherence tomography was performed to confirm the diagnosis...
2017: Advanced Biomedical Research
https://www.readbyqxmd.com/read/29142750/evaluation-of-epidermal-growth-factor-receptor-serum-levels-and-their-association-with-clinicopathological-characteristics-in-patients-with-colorectal-cancer
#7
Mehmet Karabulut, Cigdem Usul Afsar, Halil Alıs, Ebru Oran, Senem Karabulut, Cevher Akarsu, Nuri Alper Sahbaz, Alpen Yahya Gümüsoglu, Elif Bilgin, Nuri Faruk Aykan
Colorectal cancer (CRC) is a major public health concern and one of the leading causes of cancer-related mortality worldwide. The aim of the present study was to determine the serum epidermal growth factor receptor (sEGFR) levels in healthy volunteers and patients with CRC, to determine the association between tumor marker levels and clinicopathological findings, and investigate its prognostic value. A total of 140 patients with CRC were enrolled in the present study. Pre-treatment sEGFR levels were determined using ELISA...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29142567/outcomes-of-intravitreal-bevacizumab-and-macular-photocoagulation-for-treatment-of-diabetic-macular-edema-in-a-tertiary-care-eye-hospital-karachi
#8
Adil Salim Jafri, Aziz-Ur-Rehman, Abdul Haleem Mirani, Saleh Memon
Objective: To study the outcomes of intravitreal injection of Bevacizumab and laser photocoagulation in the treatment of diabetic macular edema (DME). Methods: Seventy-two eyes of 59 patients with diabetic macular edema were divided into two groups of 41 eyes (Group-A) and 31 eyes (Group-B). Subjects in group-A were treated with three intravitreal injections of Bevacizumab (IVB), and that of group-B with macular photocoagulation. Duration of study was 9 months. Follow up pattern for both groups was1, 2, 3 and 6 months...
September 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29142182/a-real-world-retrospective-cohort-study-of-combined-therapy-with-bevacizumab-and-paclitaxel-in-japanese-patients-with-metastatic-breast-cancer
#9
Hirofumi Yamada, Kenichi Inoue, Shigenori E Nagai, Maki Nakai, Fumio Arisawa, Hiroyuki Ueda, Tsuyoshi Saito, Jun Ninomiya, Toru Kuroda, Takashi Sakurai, Hitomi Kodama, Kei Kimizuka, Satoshi Hata, Toshihiro Kai, Masafumi Kurosumi
OBJECTIVE: Combined therapy with bevacizumab and paclitaxel (BP regimen) as a first-line treatment has proven highly effective with good tolerance for patients with metastatic breast cancer (MBC). The objective of this study was to examine the efficacy and safety of the BP regimen for Japanese patients with MBC in real-world clinical settings. METHODS: From June 2012 through May 2014, we recruited 94 patients at 10 medical institutions. The primary endpoint was time to treatment failure (TTF), and the secondary endpoints were overall survival (OS) and safety...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29141164/lomustine-and-bevacizumab-in-progressive-glioblastoma
#10
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C Bromberg, Michael Platten, Martin Klein, Martin J van den Bent
BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS: We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients)...
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29140135/pseudoprogression-on-bevacizumab-treatment-tumor-dynamics-in-the-modern-era-of-systemic-treatment-for-metastatic-colorectal-cancer
#11
Cornelis J A Punt, Joost Huiskens, Thomas van Gulik, Marc Engelbrecht
No abstract text is available yet for this article.
November 15, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29138948/correction-to-s-1-and-irinotecan-plus-bevacizumab-as-second-line-chemotherapy-for-patients-with-oxaliplatin-refractory-metastatic-colorectal-cancer-a-multicenter-phase-ii-study-in-japan-kscc1102
#12
Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, Soichiro Maekawa, Hirofumi Kawanaka, Masaki Kitazono, Eiji Oki, Yasunori Emi, Hidetsugu Murakami, Yutaka Ogata, Hiroshi Saeki, Mototsugu Shimokawa, Shoji Natsugoe, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara
In the original publication, in Abstract, the sentence that reads as, "Oral S-1 at a dose of 80 mg/m(2) was…………. drug-free interval" should read as, "Oral S-1 at a dose of 40 mg/m(2) was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.
November 14, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29138383/-a-case-of-locally-advanced-breast-cancer-successfully-treated-with-local-control-that-achieved-a-pathological-complete-response-after-bevacizumab-and-paclitaxel-combination-chemotherapy
#13
Nozomi Ueno, Seiko Suzushino, Tsukasa Kubo, Akihito Abe, Jun Ito, Mitsuhiko Yasuda, Hiroyuki Kato
A 68-year-old woman with a 5-year history of an untreated left breast tumor presented to our hospital. She was admitted for untreated diabetes and severe anemia. The cause of the anemia was bleeding from the tumor, and she was referred to our department. She was diagnosed with T4bN0M0, stage IIIb breast cancer. First, we initiated hormonal therapy. However, the tumor did not decrease in size. We then administered chemotherapy. The tumor markedly decreased in size, and mastectomy and axillary lymph node dissection were performed...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29137021/effect-of-antitumor-treatments-on-triple-negative-breast-cancer-patients-a-prisma-compliant-network-meta-analysis-of-randomized-controlled-trials
#14
Qiuhong Tian, Peng Du, Sen Li, Zhenzhu Bai, Yong Yang, Jinsheng Zeng
BACKGROUND: Triple-negative breast cancer (TNBC) lacks the expression of the estrogen receptor, progesterone receptor, and receptor tyrosine-protein kinase erbB-2 (HER2/neu), which renders hormone-related endocrine and targeted therapy essentially futile. OBJECTIVE: We performed a meta-analysis to assess the effects of antitumor regimens in the treatment of TNBC patients. METHODS: We searched electronic databases, including PubMed, Embase, and the Cochrane Library, through January 2017 using the following keywords: "triple negative breast cancer," "TNBC," and "random*" without language restrictions...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29135615/diffusion-of-bevacizumab-across-oncology-practices-an-observational-study
#15
Nancy L Keating, Haiden A Huskamp, Deborah Schrag, John M McWilliams, Barbara J McNeil, Bruce E Landon, Michael E Chernew, Sharon-Lise T Normand
BACKGROUND: Technological advances can improve care and outcomes but are a primary driver of health care spending growth. Understanding diffusion and use of new oncology therapies is important, given substantial increases in prices and spending on such treatments. OBJECTIVES: Examine diffusion of bevacizumab, a novel (in 2004) and high-priced biologic cancer therapy, among US oncology practices during 2005-2012 and assess variation in use across practices. RESEARCH DESIGN: Population-based observational study...
November 10, 2017: Medical Care
https://www.readbyqxmd.com/read/29135093/evaluation-of-safety-of-bevacizumab-as-second-line-treatment-of-patients-with-metastatic-colorectal-cancer
#16
Vladimir Todorovic, Nada Cicmil Saric, Jadranka Lakicevic, Milan Sorat
PURPOSE: Bevacizumab is a relatively new monoclonal antibody introduced in the treatment of metastatic colorectal cancer (CRC). Since varied efficiency and adverse events of this drug were reported, the purpose of this study was to assess the safety of bevacizumab as second-line treatment of patients with metastatic CRC. METHODS: This observational, non-interventional study involved 35 patients with metastatic CRC treated with bevacizumab. Patients were from the Oncology Clinic, Clinical Centre of Montenegro...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#17
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29134647/serial-profiling-of-circulating-tumor-dna-for-optimization-of-anti-vegf-chemotherapy-in-metastatic-colorectal-cancer-patients
#18
Masami Yamauchi, Yuji Urabe, Atsushi Ono, Daiki Miki, Hidenori Ochi, Kazuaki Chayama
Understanding the molecular changes in tumors in response to anti-VEGF chemotherapy is crucial for optimization of the treatment strategy for metastatic colorectal cancer. We prospectively investigated changes in the amount and constitution of circulating tumor DNA (ctDNA) in serial peripheral blood samples during chemotherapy. Sixty-one plasma samples taken at different time points (baseline, remission, and post-progression) and pre-treatment tumor samples were collected from 21 patients who received bevacizumab-containing first-line chemotherapy...
November 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29134372/systematic-review-of-cytoreductive-surgery-and-bevacizumab-containing-chemotherapy-in-advanced-ovarian-cancer-focus-on-safety
#19
REVIEW
Marco Petrillo, Camilla Nero, Vittoria Carbone, Matteo Bruno, Giovanni Scambia, Anna Fagotti
BACKGROUND: Initial experiences reported increased surgical morbidities in patients receiving cytoreductive surgery for colorectal cancer after bevacizumab-containing chemotherapy; however, more recent literature suggests a favorable toxicity profile in patients with advanced ovarian cancer (AOC). With the aim of providing a more objective point of view on this controversial issue, we present here a systematic literature review. METHODS: Systematic revision of the available literature was conducted using the PubMed, MEDLINE, and EMBASE electronic databases...
November 13, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29134182/high-dose-2-5-mg-intravitreal-bevacizumab-as-rescue-therapy-for-persistent-postradiation-cystoid-macular-edema
#20
Mohammed Ali Khan, Arman Mashayekhi, Kyle Ferguson, Jerry A Shields, Carol L Shields
Background/Aims: To investigate the efficacy of intravitreal high-dose (2.5 mg/0.1 mL) bevacizumab as rescue therapy for postradiation cystoid macular edema (CME) resistant to standard-dose (1.25 mg/0.05 mL) bevacizumab. Methods: Retrospective, interventional case series. Results: Fifteen eyes of 15 patients were included. Eyes were treated with a mean of 10 standard-dose (1.25 mg) bevacizumab injections but failed to show CME resolution. Following 3 monthly treatments of high-dose (2...
September 2017: Ocular Oncology and Pathology
keyword
keyword
1763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"